UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 426

Sortiert nach

Disialoganglioside GD2 Expression in Solid Tumors and Role as a Target for Cancer Therapy

Frontiers in oncology, 2020-07, Vol.10, p.1000

2020

Link zum Volltext

Verfügbarkeit prüfen

SCLC Classification by Platinum Sensitivity in the Era of Immunotherapy: Mere Relic or a Valuable Treasure to Keep?

Journal of thoracic oncology, 2024-02, Vol.19 (2), p.193-195

Owonikoko, Taofeek K

2024

Link zum Volltext

Verfügbarkeit prüfen

Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451

Journal of clinical oncology, 2021-04, Vol.39 (12), p.1349-1359

2021

Link zum Volltext

Verfügbarkeit prüfen

Lung cancer: New biological insights and recent therapeutic advances

CA: a cancer journal for clinicians, 2011-03, Vol.61 (2), p.91-112

2011

Link zum Volltext

Verfügbarkeit prüfen

Comparison of the toxicity profile of PD‐1 versus PD‐L1 inhibitors in non–small cell lung cancer: A systematic analysis of the literature

Cancer, 2018-01, Vol.124 (2), p.271-277

2018

Link zum Volltext

Verfügbarkeit prüfen

An update on the immune landscape in lung and head and neck cancers

CA: a cancer journal for clinicians, 2020-11, Vol.70 (6), p.505-517

2020

Link zum Volltext

Verfügbarkeit prüfen

The PLAG1-GDH1 Axis Promotes Anoikis Resistance and Tumor Metastasis through CamKK2-AMPK Signaling in LKB1-Deficient Lung Cancer

Molecular cell, 2018-01, Vol.69 (1), p.87-99.e7

2018

Link zum Volltext

Verfügbarkeit prüfen

Benefits and limitations of real-world evidence: lessons from EGFR mutation-positive non-small-cell lung cancer

Future oncology (London, England), 2021-03, Vol.17 (8), p.965-977

2021

Link zum Volltext

Verfügbarkeit prüfen

Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1–targeted therapy in lung cancer patients

Proceedings of the National Academy of Sciences - PNAS, 2017-05, Vol.114 (19), p.4993-4998

2017

Link zum Volltext

Verfügbarkeit prüfen

Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment

Cancer letters, 2016-10, Vol.380 (2), p.494-504

2016

Link zum Volltext

Verfügbarkeit prüfen

Expression of tdTomato and luciferase in a murine lung cancer alters the growth and immune microenvironment of the tumor

PloS one, 2021-08, Vol.16 (8), p.e0254125-e0254125

2021

Link zum Volltext

Verfügbarkeit prüfen

Rescue of exhausted CD8 T cells by PD-1–targeted therapies is CD28-dependent

Science (American Association for the Advancement of Science), 2017-03, Vol.355 (6332), p.1423-1427

2017

Link zum Volltext

Verfügbarkeit prüfen

Overcoming Acquired Resistance to AZD9291, A Third-Generation EGFR Inhibitor, through Modulation of MEK/ERK-Dependent Bim and Mcl-1 Degradation

Clinical cancer research, 2017-11, Vol.23 (21), p.6567-6579

2017

Link zum Volltext

Verfügbarkeit prüfen

Immune checkpoint inhibitors in small cell lung cancer

Journal of thoracic disease, 2018-02, Vol.10 (Suppl 3), p.S460-S467

2018

Link zum Volltext

Verfügbarkeit prüfen

Inhibitors of mTOR pathway for cancer therapy, moving on from rapalogs to TORKinibs

Cancer, 2015-10, Vol.121 (19), p.3390-3392

Owonikoko, Taofeek K.

2015

Link zum Volltext

Verfügbarkeit prüfen

Randomized Phase II Trial of Cisplatin and Etoposide in Combination With Veliparib or Placebo for Extensive-Stage Small-Cell Lung Cancer: ECOG-ACRIN 2511 Study

Journal of clinical oncology, 2019-01, Vol.37 (3), p.222-229

2019

Link zum Volltext

Verfügbarkeit prüfen

Targeting c-Myc to Overcome Acquired Resistance of EGFR Mutant NSCLC Cells to the Third-Generation EGFR Tyrosine Kinase Inhibitor, Osimertinib

Cancer research (Chicago, Ill.), 2021-09, Vol.81 (18), p.4822-4834

2021

Link zum Volltext

Verfügbarkeit prüfen

Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study

Journal of clinical oncology, 2023-06, Vol.41 (16), p.2893-2903

2023

Link zum Volltext

Verfügbarkeit prüfen

The clinical conundrum of managing relapsed small cell lung cancer

Cancer, 2019-04, Vol.125 (7), p.1022-1026

2019

Link zum Volltext

Verfügbarkeit prüfen

MAST1 Drives Cisplatin Resistance in Human Cancers by Rewiring cRaf-Independent MEK Activation

Cancer cell, 2018-08, Vol.34 (2), p.315-330.e7

2018

Link zum Volltext

Verfügbarkeit prüfen

Lung Cancer in Elderly Patients: An Analysis of the Surveillance, Epidemiology, and End Results Database

Journal of clinical oncology, 2007-12, Vol.25 (35), p.5570-5577

2007

Link zum Volltext

Verfügbarkeit prüfen

Characteristics and Outcomes of Patients With Metastatic KRAS-Mutant Lung Adenocarcinomas: The Lung Cancer Mutation Consortium Experience

Journal of thoracic oncology, 2019-05, Vol.14 (5), p.876-889

2019

Link zum Volltext

Verfügbarkeit prüfen

Sites of metastasis and association with clinical outcome in advanced stage cancer patients treated with immunotherapy

BMC cancer, 2019-08, Vol.19 (1), p.857-857, Article 857

2019

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 426

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(404)
Mit Volltextzugriff
(420)

Publikationsform

Sprache

Englisch
(423)
Japanisch
(46)

Erscheinungsjahr

n.n

Thema

Science & Technology
(198)
Life Sciences & Biomedicine
(189)
Humans
(174)
Oncology
(166)
Female
(87)
Male
(84)
Aged
(66)
Lung Cancer
(64)
Middle Aged
(64)
Lung Neoplasms - Drug Therapy
(60)
Lung Neoplasms - Pathology
(59)
Tumors
(50)
Cancer
(49)
Adult
(46)
Animals
(43)
Carcinoma, Non-Small-Cell Lung - Pathology
(39)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(36)
Cell Line, Tumor
(36)
Aged, 80 And Over
(33)
Mutation
(33)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Journal Of Clinical Oncology
(119)
Cancer Research
(38)
Cancer
(32)
Journal Of Thoracic Oncology
(28)
Clinical Lung Cancer
(13)
Clinical Cancer Research
(11)
The Oncologist
(11)
The Journal Of Clinical Investigation
(7)
Cancer Letters
(6)
Journal For Immunotherapy Of Cancer
(6)

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Disialoganglioside GD2 Expression in Solid Tumors and Role as a Target for Cancer Therapy

SCLC Classification by Platinum Sensitivity in the Era of Immunotherapy: Mere Relic or a Valuable Treasure to Keep?

Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451

Lung cancer: New biological insights and recent therapeutic advances

Comparison of the toxicity profile of PD‐1 versus PD‐L1 inhibitors in non–small cell lung cancer: A systematic analysis of the literature

An update on the immune landscape in lung and head and neck cancers

The PLAG1-GDH1 Axis Promotes Anoikis Resistance and Tumor Metastasis through CamKK2-AMPK Signaling in LKB1-Deficient Lung Cancer

Benefits and limitations of real-world evidence: lessons from EGFR mutation-positive non-small-cell lung cancer

Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1–targeted therapy in lung cancer patients

Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment

Expression of tdTomato and luciferase in a murine lung cancer alters the growth and immune microenvironment of the tumor

Rescue of exhausted CD8 T cells by PD-1–targeted therapies is CD28-dependent

Overcoming Acquired Resistance to AZD9291, A Third-Generation EGFR Inhibitor, through Modulation of MEK/ERK-Dependent Bim and Mcl-1 Degradation

Immune checkpoint inhibitors in small cell lung cancer

Inhibitors of mTOR pathway for cancer therapy, moving on from rapalogs to TORKinibs

Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer

Randomized Phase II Trial of Cisplatin and Etoposide in Combination With Veliparib or Placebo for Extensive-Stage Small-Cell Lung Cancer: ECOG-ACRIN 2511 Study

Targeting c-Myc to Overcome Acquired Resistance of EGFR Mutant NSCLC Cells to the Third-Generation EGFR Tyrosine Kinase Inhibitor, Osimertinib

Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study

The clinical conundrum of managing relapsed small cell lung cancer

Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial

MAST1 Drives Cisplatin Resistance in Human Cancers by Rewiring cRaf-Independent MEK Activation

Lung Cancer in Elderly Patients: An Analysis of the Surveillance, Epidemiology, and End Results Database

Characteristics and Outcomes of Patients With Metastatic KRAS-Mutant Lung Adenocarcinomas: The Lung Cancer Mutation Consortium Experience

Sites of metastasis and association with clinical outcome in advanced stage cancer patients treated with immunotherapy

Suchergebnisse filtern